Keyphrases
Aggression
9%
Akathisia
23%
Amantadine
15%
Antipsychotics
30%
Augmentation Therapy
15%
Beneficial Effects
8%
Benign Paroxysmal Positional Vertigo
22%
Blood Pressure
8%
Cannabis
8%
Clozapine
15%
Comorbid
24%
Corneal Temperature
22%
Dehydroepiandrosterone
15%
Depressive Symptoms
9%
Dizziness
8%
Donepezil
15%
Drug-free
12%
DSM-IV
9%
Electroconvulsive Therapy
30%
Escitalopram
15%
Extrapyramidal Symptoms
8%
Israel
9%
Major Depressive Disorder
9%
Mental Status
15%
Monotherapy
9%
Negative Symptoms
12%
Negative Syndrome
15%
Obsessive-compulsive
10%
Obsessive-compulsive Disorder
26%
Obsessive-compulsive Symptoms
10%
Olanzapine
22%
Patients with Schizophrenia
21%
Placebo
12%
Placebo-controlled
8%
Psychiatric Disorders
9%
Psychiatric Ward
8%
Psychiatrists
9%
Psychosis
17%
Psychotic
11%
Psychotic Patients
11%
Randomized Placebo-controlled Trial
8%
Schizophrenia
80%
Schizophrenic Patients
100%
Selective Serotonin Reuptake Inhibitors
17%
Trazodone
22%
Treatment-resistant Depression
9%
Treatment-resistant Schizophrenia
15%
Violence
10%
Violent Behavior
8%
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
14%
Neuroscience
5-HT2A Antagonists
7%
Akathisia
23%
Amantadine
15%
Antidepressant
12%
Antipsychotic
59%
Attention Deficit Hyperactivity Disorder
7%
Behavior (Neuroscience)
8%
Benign Paroxysmal Positional Vertigo
7%
Blood Plasma
16%
Brain Imaging
7%
Brainstem
7%
Cannabis
8%
Cerebrovascular Accident
8%
Chloral Hydrate
7%
Chromosome 10p
7%
Clozapine
15%
Creatine Kinase
7%
Crossover Study
15%
Dehydroepiandrosterone
15%
Donepezil
15%
Electroconvulsive Therapy
30%
Escitalopram
15%
Extrapyramidal Symptoms
8%
In Vivo
7%
Magnetic Resonance Imaging of Brain
7%
Major Depressive Disorder
8%
Mental Disorder
22%
Negative Syndrome
32%
Norepinephrine
7%
Obsessive-Compulsive Disorder
26%
Olanzapine
7%
Parkinson's Disease
8%
Phosphatidylinositide
7%
Placebo
25%
Platelet
15%
Positive Syndrome
28%
Propranolol
7%
Psychopathology
19%
Selective Serotonin Reuptake Inhibitor
23%
Selegiline
7%
Serotonin Reuptake Inhibitor
8%
Somatoform Disorder
7%
Systemic Lupus Erythematosus
7%
Thermoregulation
9%
Transcranial Magnetic Stimulation
7%
Trazodone
22%
Treatment-Resistant Depression
7%
Treatment-Resistant Schizophrenia
15%
Typical Antipsychotic
43%
Vesicular Monoamine Transporter
7%
Pharmacology, Toxicology and Pharmaceutical Science
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
7%
Akathisia
23%
Amantadine
15%
Antipsychotic
45%
Antipsychotic Drug
10%
Attention Deficit Disorder
7%
Automutilation
7%
Bupropion
7%
Cannabinoid
7%
Cannabis
8%
Chloral Hydrate
7%
Cholinergic Receptor Stimulating Agent
6%
Clozapine
7%
Creatine Kinase
7%
Diseases
10%
Donepezil
15%
Dopamine Receptor Stimulating Agent
6%
Endocannabinoid
7%
Equus
7%
Escitalopram
7%
Extrapyramidal Symptoms
8%
Inflammation
7%
Major Depression
7%
Monotherapy
12%
Negative Syndrome
15%
Obsessive Compulsive Disorder
11%
Olanzapine
22%
Pathophysiology
7%
Placebo
28%
Positive Syndrome
11%
Posttraumatic Stress Disorder
7%
Prasterone
15%
Prevalence
10%
Propranolol
7%
Risperidone
7%
Selective Serotonin Reuptake Inhibitor
14%
Serotonin 2A Antagonist
7%
Serotonin Reuptake Inhibitor
7%
Sexual Dysfunction
7%
Social Phobia
7%
Symptomatology
9%
Trazodone
22%
Treatment Resistant Depression
7%
Treatment-Resistant Schizophrenia
7%
Typical Antipsychotic
37%
Vertigo
7%
Vesicular Monoamine Transporter
7%
Vesicular Monoamine Transporter 2
7%
Zolmitriptan
7%
Zuclopenthixol Acetate
7%